Enrofloxacin (ENR) is a fluoroquinolone antibiotic that is also used in veterinary medicine. The Bayer Corporation sells it under the brand name Baytril. The US Food and Drug Administration has licenced ENR for the treatment of individual pets and domestic animals in the United States (FDA). Pseudomonas aeruginosa, Klebsiella, and E.coli are just a few of the gram-positive and gram-negative bacteria that ENR can kill. It's used to treat skin and soft tissue infections, urinary tract infections in dogs and cats, Chlamydophila felis infections in cats, and Escherichia coli ulcerative colitis in dogs. Over the forecast period, significant increase in the poultry sector is expected to have a beneficial impact on enrofloxacin market growth.
This market study
covers the global and regional market with an in-depth analysis of the overall
growth prospects in the market. Furthermore, it sheds light on the comprehensive
competitive landscape of the global enrofloxacin
market. The report further offers a
dashboard overview of leading companies encompassing their successful marketing
strategies, market contribution, recent developments in both historic and
present contexts.
The market is predicted
to rise due to the increasing usage of ENR in the treatment of infections
caused by both Gram-negative and Gram-positive bacteria. Cattle get ENR by subcutaneous
injection, while pigs get it through an intramuscular injection. It is given
orally to cattle, pigs, turkeys, and chickens for the treatment of respiratory
and gastrointestinal illnesses.